title: Significance of serum concentrations of E-selectin and CA19-9 in the prognosis of colorectal cancer.
abstract: OBJECTIVE
  Interaction of CA19-9 with E-selectin is involved in initiation of hematogenous metastases. We investigated whether serum concentrations of E-selectin and CA19-9 are good predictors of hematogenous metastases and prognosis in colorectal cancer.
  
  
  METHODS
  Pre-operative serum samples were obtained from 152 patients with colorectal cancer, and from 28 healthy volunteers. Correlation between serum E-selectin and CA19-9 was studied in terms of clinically detected hematogenous metastases and prognosis of patients.
  
  
  RESULTS
  Low serum concentration of E-selectin was defined as <50 U/ml in healthy volunteers, and on that basis, 20.4% of all patients belonged to the high E-selectin group. Several distinctive characteristics were observed in the clinical course of patients with high serum concentrations of both CA19-9 and E-selectin. The rate of Dukes' D cancer was significantly higher, and curative surgery was performed less frequently in patients with high serum concentrations of both CA19-9 and E-selectin (60 and 40%) than in others. However, there was no significant difference in the frequency of recurrence after curative surgery between patients with high serum concentrations of both CA19-9 and E-selectin (25.0%) and others. Overall the 5-year survival rate was significantly lower in patients with high serum concentrations of both CA19-9 and E-selectin (34.3%) than in other patients. Even if the serum concentration of CA19-9 was high, prognosis was not poor in patients with low serum concentration of E-selectin.
  
  
  CONCLUSIONS
  These results suggested that it was useful to measure both CA19-9 and E-selectin as markers of hematogenous metastases and as predictors of prognosis in colorectal cancer.
authors.affiliation: Department of Surgery, Fujita Health University School of Medicine, Toyoake, Aichi, Japan. harsato@fujita-hu.ac.jp
authors.forename: Harunobu
authors.initials: H
authors.lastname: Sato
authors.forename: Nobuteru
authors.initials: N
authors.lastname: Usuda
authors.forename: Makoto
authors.initials: M
authors.lastname: Kuroda
authors.forename: Shuji
authors.initials: S
authors.lastname: Hashimoto
authors.forename: Morito
authors.initials: M
authors.lastname: Maruta
authors.forename: Koutarou
authors.initials: K
authors.lastname: Maeda
mesh_terms: D000230:Adenocarcinoma / Q000097:blood* / Q000556:secondary / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000097:blood* / Q000556:secondary / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018395:CA-19-9 Antigen / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000556:secondary / Q000601:surgery; D016022:Case-Control Studies; D015179:Colorectal Neoplasms / Q000097:blood* / Q000473:pathology / Q000601:surgery; D019040:E-Selectin / Q000097:blood*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate
chemical_list: D018395:CA-19-9 Antigen; D019040:E-Selectin